These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19091890)

  • 1. P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys.
    Liow JS; Kreisl W; Zoghbi SS; Lazarova N; Seneca N; Gladding RL; Taku A; Herscovitch P; Pike VW; Innis RB
    J Nucl Med; 2009 Jan; 50(1):108-15. PubMed ID: 19091890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein.
    Seneca N; Zoghbi SS; Liow JS; Kreisl W; Herscovitch P; Jenko K; Gladding RL; Taku A; Pike VW; Innis RB
    J Nucl Med; 2009 May; 50(5):807-13. PubMed ID: 19372478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.
    Kreisl WC; Liow JS; Kimura N; Seneca N; Zoghbi SS; Morse CL; Herscovitch P; Pike VW; Innis RB
    J Nucl Med; 2010 Apr; 51(4):559-66. PubMed ID: 20237038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
    Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
    J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux.
    Zoghbi SS; Liow JS; Yasuno F; Hong J; Tuan E; Lazarova N; Gladding RL; Pike VW; Innis RB
    J Nucl Med; 2008 Apr; 49(4):649-56. PubMed ID: 18344435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
    Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
    Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.
    Kannan P; Brimacombe KR; Kreisl WC; Liow JS; Zoghbi SS; Telu S; Zhang Y; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
    Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2593-8. PubMed ID: 21262843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier.
    Kannan P; Brimacombe KR; Zoghbi SS; Liow JS; Morse C; Taku AK; Pike VW; Halldin C; Innis RB; Gottesman MM; Hall MD
    Drug Metab Dispos; 2010 Jun; 38(6):917-22. PubMed ID: 20212014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ketoconazole on the biodistribution and metabolism of [11C]loperamide and [11C]N-desmethyl-loperamide in wild-type and P-gp knockout mice.
    Seneca N; Zoghbi SS; Shetty HU; Tuan E; Kannan P; Taku A; Innis RB; Pike VW
    Nucl Med Biol; 2010 Apr; 37(3):335-45. PubMed ID: 20346873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of mass of [11C]-laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein blockage at the blood-brain barrier.
    Moerman L; Dumolyn C; Boon P; De Vos F
    Nucl Med Biol; 2012 Jan; 39(1):121-5. PubMed ID: 21958857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
    Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
    Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function.
    Lazarova N; Zoghbi SS; Hong J; Seneca N; Tuan E; Gladding RL; Liow JS; Taku A; Innis RB; Pike VW
    J Med Chem; 2008 Oct; 51(19):6034-43. PubMed ID: 18783208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic Models for Measuring P-glycoprotein Function at the Blood-Brain Barrier with Positron Emission Tomography.
    Lubberink M
    Curr Pharm Des; 2016; 22(38):5786-5792. PubMed ID: 27494063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging P-glycoprotein function in rats using [(11)C]-N-desmethyl-loperamide.
    Farwell MD; Chong DJ; Iida Y; Bae SA; Easwaramoorthy B; Ichise M
    Ann Nucl Med; 2013 Aug; 27(7):618-24. PubMed ID: 23572210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with (11)C-desmethylloperamide.
    Moerman L; Wyffels L; Slaets D; Raedt R; Boon P; De Vos F
    Epilepsy Res; 2011 Mar; 94(1-2):18-25. PubMed ID: 21277169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [
    Mairinger S; Leterrier S; Filip T; Löbsch M; Pahnke J; Hernández-Lozano I; Stanek J; Tournier N; Zeitlinger M; Hacker M; Langer O; Wanek T
    J Cereb Blood Flow Metab; 2024 Jan; 44(1):142-152. PubMed ID: 37728771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-yield route to synthesize the P-glycoprotein radioligand [11C]N-desmethyl-loperamide and its parent radioligand [11C]loperamide.
    Wang M; Gao M; Zheng QH
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5259-63. PubMed ID: 23981899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.
    Ke AB; Eyal S; Chung FS; Link JM; Mankoff DA; Muzi M; Unadkat JD
    J Nucl Med; 2013 Mar; 54(3):437-46. PubMed ID: 23359659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
    Sugimoto H; Hirabayashi H; Amano N; Moriwaki T
    Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.